Anti Infective Agents Impact in COVID-19 Pneumonia

Study Overview
=================
Brief Summary
-----------------
During COVID-19 epidemic, hydroxychloroquine was proposed and authorized as a possible key agent in the treatment of COVID-19 hospitalized pneumonia, including in France. Gautret et al. proposed the combination regimen with azithromycin. However only one study reported the interest of azithromycin alone. Retrospective study reporting the impact of the anti-infective agents used during the pandemic in a tertiary care hospital, using azithromycin with or without hydroxychloroquine.

Official Title
-----------------
Interest of Azithromycin With or Without Hydroxychloroquine for the Treatment of COVID-19 Pneumonia : a Retrospective Observational Study

Conditions
-----------------
COVID, Pneumonia, Viral

Intervention / Treatment
-----------------
* Drug: favorable outcome


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged over 18 years old hospitalized for a COVID-19 pneumonia documented by PCR or lung tomodensitometry, admitted outside an intensive care unit, in a medicine ward Exclusion Criteria: patient opposed to data collected, or who could not consent because of a serious presentation of the pneumonia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Azithromycin or non-azithromycin group<br>Patient who received during admission for a severe COVID-19 pneumonia, azithromycin +/-hydroxychloroquine or no azithromycin. | Drug: favorable outcome<br>* Whether patient under such regimen had a favorable outcome (no transfer in intensive care unit or death)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Favorable outcome | After being admitted, patient was monitored whether he does not required to be transferred in ICU or died because of a severe COVID-19 pneumonia within 7 days. The outcome was purely clinical. If patient was discharged at home after admission and/or was transferred into a rehabilitation center he was considered as a favorable outcome independently of any biological marker. | Assessed within 7 days after admission | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk factors 1 | Studying if biological abnormalities (lymphocyte count or CRP) at admission were associated with an unfavorable outcome | Assessed at day 1 | 
| Risk factors 2 | Studying if comorbidities were associated with an unfavorable outcome | Assessed at day 1 | 
| Interest of anti-infective agents | Studying whether any regimen was associated with a favorable outcome (including azithromycin) | From date of inclusion until the date of first documented progression to ICU or date of death from any cause, whichever came first, assessed up to 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
azithromycin, hydroxychloroquine, COVID-19, pneumonia, hospitalization